Maribavir: Difference between revisions
From IDWiki
(Created page with "* Class is benzimidazole riboside * Mechanism of action is inhibition of UL97-mediated phosphorylation of nuclear lamin A/C * Main indication is CMV prophylaxis in solid-o...") |
m (Text replacement - "([Ss])olid-organ" to "$1olid organ") |
||
| Line 1: | Line 1: | ||
* Class is benzimidazole riboside |
* Class is benzimidazole riboside |
||
* Mechanism of action is inhibition of UL97-mediated phosphorylation of nuclear lamin A/C |
* Mechanism of action is inhibition of UL97-mediated phosphorylation of nuclear lamin A/C |
||
* Main indication is [[CMV]] prophylaxis in solid |
* Main indication is [[CMV]] prophylaxis in solid organ transplant |
||
== Further Reading == |
== Further Reading == |
||
* Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid |
* Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study. ''Clin Infect Dis''. 2019;68(8):1255–1264. DOI: [https://doi.org/10.1093/cid/ciy706 10.1093/cid/ciy706] |
||
[[Category:Antivirals]] |
[[Category:Antivirals]] |
||
Latest revision as of 01:03, 7 August 2020
- Class is benzimidazole riboside
- Mechanism of action is inhibition of UL97-mediated phosphorylation of nuclear lamin A/C
- Main indication is CMV prophylaxis in solid organ transplant
Further Reading
- Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study. Clin Infect Dis. 2019;68(8):1255–1264. DOI: 10.1093/cid/ciy706
